



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Revlimid® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information (required)					
<b>Select the diagnosis below:</b>					
<input type="checkbox"/> Anemia due to myelodysplastic syndrome (MDS)					
<input type="checkbox"/> Mantle cell lymphoma (MCL)					
<input type="checkbox"/> Multiple myeloma (MM)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Clinical Information:</b>					
Is this request for continuation of prior Revlimid therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient used Revlimid within the past 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is Revlimid prescribed by or in consultation with an oncologist/hematologist? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For treatment of anemia due to myelodysplastic syndrome (MDS), also answer the following:</b>					
Does the patient have transfusion-dependent anemia? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select the type of MDS that applies to the patient:					
<input type="checkbox"/> MDS associated WITH a deletion 5q					
<input type="checkbox"/> Low- or intermediate-1-risk					
<input type="checkbox"/> MDS WITHOUT a deletion 5q					
<input type="checkbox"/> Serum erythropoietin level is greater than 500 mU/mL					
<input type="checkbox"/> Serum erythropoietin level is less than or equal to 500 mU/mL					
<input type="checkbox"/> Patient has had trial and failure, contraindication, or intolerance to at least one erythropoietin agent [e.g., Aranesp (darboepoetin alfa), Epogen or Procrit (epoetin alfa)]					
<b>For mantle cell lymphoma (MCL), also answer the following:</b>					
Does the patient have relapsed, refractory, or progressed disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient had at least one prior mantle cell lymphoma therapy [e.g., Velcade (bortezomib), Treanda (bendamustine), cladribine, Rituxan (rituximab)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For multiple myeloma, also answer the following:</b>					
Will Revlimid be used in combination with dexamethasone? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will Revlimid be used as maintenance therapy following autologous hematopoietic stem cell transplantation (auto-HSCT)? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Revlimid\_CMS\_2019Jan-W



## Revlimid<sup>®</sup> Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**Quantity Limit:**

What is the quantity requested per DAY? \_\_\_\_\_

**What is the reason for exceeding the plan limitations?**

- Titration or loading-dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same dosage and remain within the same dosing frequency. **Please specify:** \_\_\_\_\_
- Other: \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

---

Please note:

This request may be denied unless all required information is received.

If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Revlimid\_CMS\_2019Jan-W